ArticleHemaSphere2025
A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia.
Article in HemaSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Scaffold-free three-dimensional culture of chronic lymphocytic leukaemia preserves B-T-cell cross-talk and enables drug response profiling.British journal of haematology · 2026Article
- Next-generation models for lymphoid malignancies: the rise of 3D culture systems in translational hematology.British journal of cancer · 2026Review
- A 3D lymph node model for chronic lymphocytic leukaemia recapitulates microenvironmental features and drug response in vitro.Disease models & mechanisms · 2026Article
- Nanoengineered 3D culture substrate enables superior persistence and polyclonal engraftment of genetically engineered hematopoietic stem cells.Cell stem cell · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic lymphocytic leukemia (CLL) B cells are characterized by a propensity to undergo rapid apoptosis when cultured in vitro, underscoring the importance of the tissue microenvironment for disease survival. One of the major limitations in studying the role of the microenvironment in tumor development and drug response is the inadequacy of conventional two-dimensional (2D) in vitro assays to physiologically reconstruct the complex spatial organization and interactions of cells in their natural lymphoid niches. To overcome this limitation, we developed a novel in vitro 3D lymph node-like spheroid model of the leukemic microenvironment by culturing human CLL cells with fibroblastic reticular cells (FRCs). FRCs are a key structural component of secondary lymphoid organs and are emerging as crucial players in tissue homeostasis and immune responses. Our results demonstrate that CLL spheroids maintain the physiological cellular ratio between FRCs and leukemic cells over time and protect tumor cells from apoptosis by mimicking the protective effects of the microenvironment. This was further demonstrated by venetoclax treatment that showed reduced apoptosis in 3D compared to a 2D setting. Importantly, the spheroids promote a gene expression profile more aligned with that of CLL cells in lymphoid tissues. The spheroid model provides a straightforward, quick-to-use platform for investigating drug efficacy under conditions that better replicate the natural lymph node microenvironment. This 3D lymph node-like spheroid model could serve as a valuable tool for studying tumor biology and the protective effects of the stromal microenvironment, and for testing therapeutic strategies in a more clinically relevant setting.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.